Document Type and Number:
Japanese Patent JPWO2023002944
Kind Code:
A1
Abstract:
[Problem] The present invention addresses the problem of providing a novel antibody that can prevent and/or treat SARS or COVID-19 infection. Provided is an antibody which comprises heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:1, heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:2, heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:3, light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:4, light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:5, and light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:6 and which is capable of binding to a receptor binding domain (RBD) of S1 subunit of SARS-CoV or SARS-CoV-2, or an antibody fragment of the antibody.
Application Number:
JP2023536736A
Publication Date:
January 26, 2023
Filing Date:
July 15, 2022
Export Citation:
